TY - JOUR
T1 - Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma
T2 - an EORTC gynecological cancer cooperative group study
AU - George, M.
AU - Scotto, V.
AU - Carnino, F.
AU - Dodion, P.
AU - Ten Bokkel Huinink, W. W.
AU - Rotmensz, N.
AU - Vermorken, J. B.
PY - 1987
Y1 - 1987
N2 - Sixteen patients with advanced ovarian carcinoma were treated with anaxirone (1,2,4-trigycidyl urazol, TGU), 600 mg/m2 every 4 weeks. Anaxirone was the second or later line of therapy. All patients had evaluable tumors and evidence of failure of prior therapy. None of the patients responded. Two had stabilization of the disease for 4 months. In one patient WHO grade 4 leukopenia and grade 4 thrombocytopenia were observed after the second TGU cycle starting on day 41 and persisted until the patient died due to tumor progression (day 50). No patient experienced thrombophlebitis.
AB - Sixteen patients with advanced ovarian carcinoma were treated with anaxirone (1,2,4-trigycidyl urazol, TGU), 600 mg/m2 every 4 weeks. Anaxirone was the second or later line of therapy. All patients had evaluable tumors and evidence of failure of prior therapy. None of the patients responded. Two had stabilization of the disease for 4 months. In one patient WHO grade 4 leukopenia and grade 4 thrombocytopenia were observed after the second TGU cycle starting on day 41 and persisted until the patient died due to tumor progression (day 50). No patient experienced thrombophlebitis.
UR - http://www.scopus.com/inward/record.url?scp=0023216406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023216406&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(87)90293-8
DO - 10.1016/0277-5379(87)90293-8
M3 - Article
C2 - 3653204
AN - SCOPUS:0023216406
VL - 23
SP - 867
EP - 869
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 6
ER -